We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
-$263M
Cap. Flow
-$30.3M
Cap. Flow %
-2.33%
Top 10 Hldgs %
46.95%
Holding
119
New
12
Increased
27
Reduced
37
Closed
33

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$41.1M
2
MASI
Masimo
MASI
+$40.1M
3
GSK icon
GSK
GSK
+$30.1M
4
HCA icon
HCA Healthcare
HCA
+$15.7M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$15.4M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$22.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.8M
3
UTHR icon
United Therapeutics
UTHR
+$19M
4
NVST icon
Envista
NVST
+$12.9M
5
HUM icon
Humana
HUM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 78.97%
2 Miscellaneous 18.23%
3 Industrials 2.8%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$85.5B
$15.9M 1.22%
32,451
-1,843
-5% -$842K
DXCM icon
27
DexCom
DXCM
$34.3B
$14.5M 1.12%
113,616
+88,012
+344% +$9.63M
GH icon
28
Guardant Health
GH
$21.7B
$14.1M 1.08%
213,203
+112,869
+112% +$7.72M
IQV icon
29
IQVIA
IQV
$43.1B
$13.8M 1.06%
59,570
+34,952
+142% +$8.28M
ILMN icon
30
Illumina
ILMN
$32.6B
$13.5M 1.04%
+39,844
New +$13.5M
XENE icon
31
Xenon Pharmaceuticals
XENE
$5.81B
$12.5M 0.96%
410,021
+200,502
+96% +$6M
ICLR icon
32
Icon
ICLR
$13.1B
$11.4M 0.87%
46,816
-5,051
-10% -$1.27M
CNC icon
33
Centene
CNC
$32B
$10M 0.77%
119,170
-105,443
-47% -$8.65M
LH icon
34
Labcorp
LH
$27.2B
$10M 0.77%
44,127
-8,861
-17% -$2.08M
LQDA icon
35
Liquidia Corp
LQDA
$6.06B
$9.89M 0.76%
1,377,490
-70,408
-5% -$443K
NSTG
36
DELISTED
NanoString Technologies, Inc.
NSTG
$9.75M 0.75%
280,695
+15,000
+6% +$517K
HQY icon
37
HealthEquity
HQY
$7.97B
$9.72M 0.75%
144,140
-189,212
-57% -$10.2M
TARO
38
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$9.53M 0.73%
220,286
+39,135
+22% +$1.83M
QGEN icon
39
Qiagen
QGEN
$8.9B
$9.44M 0.73%
181,726
+28,447
+19% +$1.47M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$31.7B
$8.63M 0.66%
52,871
-17,369
-25% -$2.65M
OCDX
41
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$8.3M 0.64%
445,059
-441,081
-50% -$7.94M
ARGX icon
42
argenx
ARGX
$64B
$7.3M 0.56%
23,142
+1,646
+8% +$479K
RGEN icon
43
Repligen
RGEN
$9.95B
$6.87M 0.53%
36,521
+31,937
+697% +$6.07M
SYNH
44
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$6.59M 0.51%
81,416
-4,196
-5% -$355K
EWT icon
45
PUT
iShares MSCI Taiwan ETF
EWT
$11.7B
$6.14M 0.47%
+100,000
New +$6.41M
IONS icon
46
Ionis Pharmaceuticals
IONS
$10.1B
$5.88M 0.45%
158,806
-225,983
-59% -$7.4M
ZNTL icon
47
Zentalis Pharmaceuticals
ZNTL
$360M
$4.62M 0.36%
100,187
+37,024
+59% +$2M
EXEL icon
48
Exelixis
EXEL
$13.5B
$4.61M 0.35%
203,156
-332,544
-62% -$6.5M
IRTC icon
49
iRhythm Holdings
IRTC
$3.96B
$4.26M 0.33%
27,047
-46,122
-63% -$5.92M
MASS icon
50
908 Devices
MASS
$444M
$4.13M 0.32%
+217,149
New +$3.73M
1
2
3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Eversept Partners held 119 positions worth $1.3B, down 17% from $1.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners's Q1 2022 filing shows 12 new, 27 increased, 37 reduced and 33 closed positions. Its largest new stake was Masimo: 208,970 shares worth $30.4M. The largest sale was McKesson, an estimated $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Industrials.

  • Eversept Partners's largest Q1 2022 buy was Masimo: 208,970 shares worth $30.4M.
  • Eversept Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022, an estimated $41.1M increase.
  • Eversept Partners's biggest Q1 2022 reduction was McKesson, cutting an estimated $22.8M.
  • Eversept Partners fully exited Humana in Q1 2022, selling an estimated $12.7M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.3B portfolio in Q1 2022.
  • Eversept Partners opened 12 new positions and closed 33 in Q1 2022.
  • Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.3B.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.